Author/Editor		Košnik, Mitja; Kopač, Peter; Eržen, Renato; Bajrović, Nisera; Adamič, Katja; Lalek, Nika; Korošec, Peter; Zidarn, Mihaela
Title		Omalizumab in chronic urticaria
Type		članek
Vol. and No.		Letnik 23
Publication year		2014
Volume		str. 57-61
ISSN		1318-4458 - Acta dermatovenerologica Alpina, Panonica, et Adriatica
Language		eng
Abstract		Introduction: Chronic urticaria (CU) severely affects quality of life. If symptoms are not controlled by antihistamines, patients need immunomodulatory drugs. Recent studies show a tremendous effect of omalizumab, a monoclonal antibody against human IgE in refractory CU. Methods: We report on the use of omalizumab in four patients with CU. By reviewing medical files, we estimated the proportion of CU patients that are candidates for such treatment. We reviewed the literature to compare the dosing schedules and outcome measures used in different studies. Results: Up to 14% of CU patients referred to a tertiary center are candidates for omalizumab. Four of our CU were patients treated with doses of 150 mg/month or less, and all responded with nearly complete remission of symptoms. In the literature, 90% of patients respond to treatment, the response being obvious in days. Half of patients were able to stop all other medications, including antihistamines. More than half of patients responded well to doses of 150 mg of omalizumab every 4 to 8 weeks. In the majority of patients, the disease relapsed after discontinuation of omalizumab. Conclusions: Omalizumab should be offered to patients with refractory CU. The duration of treatment is not known.
Keywords		urticaria antihistamines omalizumab dosing schedule quality of life